NCT07522099RecruitingPhase 2
Chinese Adults With Kidney Disease
A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease
Source: ClinicalTrials.gov · Last updated 3 Sept 2026
Brief summary (registry, in English)
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 27 Feb 2026
- Start date
- 21 May 2026
- Primary completion date
- 10 Jul 2028
- Lead sponsor
- ADARx Pharmaceuticals, Inc.
- Diseases
- IgA nephropathy
- NCT number
- NCT07522099
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 21 May 2026 to the primary completion date, 10 Jul 2028
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous kidney transplant or major solid organ transplant
- Required renal replacement therapy for more than 72 hours
- Current or previous use of C5 or CFB inhibitors (such as eculizumab, ravulizumab or iptacopan)
Other illness
- History of recurrent invasive infection
- Active TB, HIV or other systemic infection
Other
- Rapidly progressive glomerular nephritis or acute kidney injury
- Abnormal liver function
Who the study is looking for
- Mean eGFR greater than or equal to 30 mL/min/1.73m2
- Clinical evidence of active kidney disease
- Treated with supportive care including an ACE inhibitor or ARB if applicable
- Willing to receive required vaccinations
- Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ADARx Clinical Site Coordinator of this site? Confirm its status | Baotou | China | Recruiting |
| ADARx Clinical Site Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| ADARx Clinical Site Coordinator of this site? Confirm its status | Guiyang | China | Recruiting |
| ADARx Clinical Site Coordinator of this site? Confirm its status | Shandong | China | Recruiting |
| ADARx Clinical Site Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
| ADARx Clinical Site Coordinator of this site? Confirm its status | Shenzhen | China | Recruiting |
| ADARx Clinical Site Coordinator of this site? Confirm its status | Wuxi | China | Recruiting |
| ADARx Clinical Site Coordinator of this site? Confirm its status | Yantai | China | Recruiting |
| ADARx Clinical Site Coordinator of this site? Confirm its status | Zhengzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.